Clinical Trials Directory

Trials / Conditions / Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

14 registered clinical trials studyying Relapsing Forms of Multiple Sclerosis — 1 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingA Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on
NCT07483632
BiogenPhase 3
CompletedA Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Rela
NCT06251986
Novartis Pharmaceuticals—
CompletedA Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Dir
NCT05798520
BiogenPhase 2
CompletedA Study of Diroximel Fumarate (DRF) in Adult Participants From the Asia-Pacific Region With Relapsing Forms of
NCT05083923
BiogenPhase 3
SuspendedEvaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosi
NCT04909502
Emerald Health PharmaceuticalsPhase 2
CompletedTime and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis
NCT04676555
Novartis Pharmaceuticals—
WithdrawnPlacebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting
NCT02428218
BiogenPhase 3
CompletedVaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multi
NCT02097849
BiogenPhase 2
CompletedPlegridy Observational Program
NCT02230969
Biogen—
CompletedEffectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
NCT01903291
Biogen—
CompletedPhase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple
NCT01873417
BiogenPhase 4
CompletedLong-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis
NCT01201356
Novartis PharmaceuticalsPhase 3
CompletedA 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5
NCT01216072
Novartis PharmaceuticalsPhase 4
CompletedA Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Su
NCT00424788
BiogenEARLY_Phase 1